Effect of the type of oil on treatment of non-alcoholic fatty liver disease

Evaluating the effects of replacing ghee with rapeseed oil on liver steatosis and enzymes, lipid profile, insulin resistance, and anthropometric measurements in patients with non-alcoholic fatty liver disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170206032417N5

Enrollment

110

Registered

2022-01-18

Start date

2022-02-04

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: The intervention group, in addition to the usual treatment, will be recommended to change their fat intake to rapeseed oil. Intervention 2: Control group: At first,

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with non-alcoholic fatty liver disease more than18 years from both sexes Patients with non-alcoholic fatty liver disease with a BMI less than 30 Patients with non-alcoholic fatty liver disease with daily ghee consumption of 3 to 8 servings

Exclusion criteria

Exclusion criteria: special diets Pregnancy and lactation during the study Viral hepatitis Alcohol consumption or history of alcohol consumption Diabetes mellitus Psychotic disorders Non-compliance to our recommendations regarding fat consumption Untreated hypothyroidism Renal Diseases Taking medications which increase GGT levels Heart failure and bone disease Alpha antitrypsin deficiency Gastrointestinal diseases such as celiac disease smoking Menopause herbal therapy

Design outcomes

Primary

Measure	Time frame
Weight. Timepoint: At weeks 0, 12. Method of measurement: Scale. kg.;Body mass index. Timepoint: At weeks 0, 12. Method of measurement: Weight(kg)/[height(m)]2 , kg/m2.;Gamma Glutamyl transferase. Timepoint: At weeks 0,12. Method of measurement: Enzymatic method , IU/ Lit.;ALP. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method , IU/ Lit.;Aspartat transaminase. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, IU/Lit.;Alanine Aminotransferase. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, IU/ Lit.;Fasting blood sugar. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, IU/ Lit.;Serum insulin. Timepoint: At weeks 0, 12. Method of measurement: Radioimmunoassay.;Waist circumference. Timepoint: At weeks 0, 12. Method of measurement: Cm.;Hepatic steatosis. Timepoint: Before intervention and three month after intervention. Method of measurement: Ultrasonography.;HDL cholesterol. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;Triglyceride. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;LDL cholesterol. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;Total cholesterol. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;HOMA-IR. Timepoint: At weeks 0, 12. Method of measurement: Formula.;Height. Timepoint: Before intervention. Method of measurement: Before intervention.	—

Measure

Time frame

Weight. Timepoint: At weeks 0, 12. Method of measurement: Scale. kg.;Body mass index. Timepoint: At weeks 0, 12. Method of measurement: Weight(kg)/[height(m)]2 , kg/m2.;Gamma Glutamyl transferase. Timepoint: At weeks 0,12. Method of measurement: Enzymatic method , IU/ Lit.;ALP. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method , IU/ Lit.;Aspartat transaminase. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, IU/Lit.;Alanine Aminotransferase. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, IU/ Lit.;Fasting blood sugar. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, IU/ Lit.;Serum insulin. Timepoint: At weeks 0, 12. Method of measurement: Radioimmunoassay.;Waist circumference. Timepoint: At weeks 0, 12. Method of measurement: Cm.;Hepatic steatosis. Timepoint: Before intervention and three month after intervention. Method of measurement: Ultrasonography.;HDL cholesterol. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;Triglyceride. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;LDL cholesterol. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;Total cholesterol. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;HOMA-IR. Timepoint: At weeks 0, 12. Method of measurement: Formula.;Height. Timepoint: Before intervention. Method of measurement: Before intervention.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Alizadeh

Oroumia University of Medical Sciences

alizadeh.m@umsu.ac.ir+98 44 3275 2375

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026